Cytokines modulate expression of cell-membrane complement inhibitory proteins in human lung cancer cell lines

American Journal of Respiratory Cell and Molecular Biology

Volumn 19, Issue 3, 1998, Pages 522-529

  Varsano, Shabtai ^a   Rashkovsky, Ludmila ^b   Shapiro, Hava ^b   Radnay, Judith ^b  

^a MEIR MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CATIONIC PROTEIN, URATE CALCIUM OXALATE STONE, HUMAN; CATIONIC PROTEIN, URATE-CALCIUM OXALATE STONE, HUMAN; CD46 PROTEIN, HUMAN; COMPLEMENT INHIBITOR; CYTOKINE; DECAY ACCELERATING FACTOR; DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 1; ION CHANNEL; LEUKOCYTE ANTIGEN; MEMBRANE COFACTOR PROTEIN; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL CULTURE; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; LUNG TUMOR; METABOLISM; PHYSIOLOGY; UPREGULATION;

ANTIGENS, CD; ANTIGENS, CD46; ANTIGENS, CD55; COMPLEMENT INACTIVATOR PROTEINS; CYTOKINES; DEXAMETHASONE; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; INTERLEUKIN-1; ION CHANNELS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0032159271     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/ajrcmb.19.3.3181     Document Type: Article

References (30)

1. Seya, T., J. Turner, and J. P. Atkinson. 1986. Purification and characterization of membrane protein (gf 45-70) that is a cofactor lor cleavage of C3b and C4b. J. Exp. Med. 163: 837-855.
2. Lublin, D. M., and J. P. Atkinson. 1989. Decay-accelerating factor: biochemistry, molecular biology and function. Annu. Rev. Immunol. 7: 35-58.
3. Davies, A., D. L. Simmons, G. Hale, R. A. Harrison, H. Tighe, P. J. Lachman, and H. Waldmann. 1989. CD59, an Ly-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med. 170: 637-654.
4. Fick, R. B., Jr., R. A. Robbins, S. U. Squier, W. E. Schoderbek, and W. D. Russ. 1986. Complement activation in cystic fibrosis respiratory fluids in vivo and in vitro generation of C5a and chemotactic activity. Pediatr. Res. 20: 1258-1268.
5. Bjornson, A. B., M. A. Mellencamp, and G. M. Schiff. 1991. Complement is activated in the upper respiratory tract during influenza virus infection. Am. Rev. Respir. Dis. 143: 1062-1066.
6. Van de Graaf, E. A., H. M. Jansen, M. M. Bakker, C. Alberts, J. K. Eeftinick Schallenkerk, and T. A. Out. 1992. ELISA of complement C3a in bronchoalveolar lavage fluid. J. Immunol. Methods 147: 241-250.
7. Andersson, M., L. Michel, J. B. Llull, and U. Pipkorn. 1994. Complement activation on the nasal mucosal surface - a feature of the immediate allergic reaction in the nose. Allergy 49: 242-245.
8. Varsano, S., I. Frolkis, and D. Ophir. 1995. Expression and distribution of cell-membrane complement regulatory glycoproteins along the human respiratory tract. Am. J. Respir. Crit. Care Med. 152: 1087-1093.
9. Varsano, S., I. Frolkis, L. Rashkovsky, D. Ophir, and Z. Fishelson. 1996. Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation. Am. J. Respir. Cell Mol. Biol. 15: 731-737.
10. Varsano, S., L. Rashkovsky, H. Shapiro, D. Ophir, and T. Mark-Bentankur. 1998. Human lung cancer cell-lines express cell-membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin. Exp. Immunol. (In press)
11. Von Biberstein, S. E., J. B. Spiro, R. Lindquist, and D. L. Kreutzer. 1996. Interleukin-receptor antagonist in head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 122: 751-759.
12. Malik, S. T. 1992. Tumor necrosis factor: roles in cancer pathophysiology. Semin. Cancer Biol. 3: 27-33.
13. Krasagakis, K., C. Garbec, C. C. Zouboulis, and C. E. Orfanos. 1995. Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res. 139: 169-182.
14. Shimomoto, H., Y. Hasegawa, Y. Nozaki, N. Takagi, T. Shibagaki, A. Nakao, and K. Shimokata. 1995. Expression of tumor necrosis factor receptors in human lung cancer cells and normal lung tissues. Am. J. Respir. Cell Mol. Biol. 13: 271-278.
15. Ardizzoia, A., P. Lissoni, F. Brivio, E. Tisi, M. S. Perego, M. G. Grassi, S. Pittalis, S. Crispino, S. Barni, and G. Toncini. 1992. Tumor necrosis factor in solid tumors: increased blood levels In the metastatic disease. J. Biol. Regul. Homeost. Agents 6: 103-107.
16. Liszweski, M. K., T. W. Post, and J. P. Atkinson. 1991. Newest member of the regulators of complement activation gene cluster. Annu. Rev. Immunol. 9: 431-455.
17. Coyne, K. E., S. E. Hall, E. S. Thompson, M. A. Arce, T. Kinoshita, T. Fujita, D. J. Anstee, W. Rosse, and D. M. Lublin. 1992. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J. Immunol. 149: 2906-2913.
18. Moutabarrik, A., I. Kakanishi, M. Namiki, T. Hara, M. Matsumoto, M. Ishibashi, A. Okuyama, D. Zaid, and T. Seya. 1993. Cytokine-mediated regulation of the surface expression of complement regulatory proteins. CD46 (MCP), CD55 (DAF), and CD59 on human vascular endothelial cells. Lymphol. Cytokine Res. 12: 167-172.
19. Bjørge, L., T. S. Jensen, E. Ulvestad, C. A. Vedeler, and R. Matre. 1995. The influence of tumor necrosis factor-α, interleukin-1β and interferon-gamma on the expression and function of the complement regulatory protein CD59 on the human colonic adenocarcinoma cell line HT29. Scand. J. Immunol. 41: 350-356.
20. Brasoveanu, L. I., M. Altomonte, A. Glogkivi, E. Fonsalti, S. Coral, A. Casparollo, R. Montagner, I. Cattarossi, C. Simonelli, A. Cattelan, V. Attadia, A. Carbone, and M. Maio. 1995. Expression of protectin (CD59) in human melanoma and its functional role in cell and complement-mediated cytotoxicity. Int. J. Cancer 61: 548-556.
21. Tandon, N., S. L. Yan, B. P. Morgan, and A. P. Weetman. 1994. Expression and function of multiple regulators of complement activation in autoimmune thyroid disease. Immunology 81: 643-647.
22. Barnes, P. J., and M. Karin. 1997. Mechanisms of disease: nuclear factor-kB -a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336: 1066-1071.
23. Hakulinen, J., and S. Meri. 1994. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab. Invest. 71: 820-827.
24. Inoue, H., M. Mizuno, T. Hesut, T. Ueki, and T. Tsuji. 1994. Distribution of complement regulatory proteins, decay-accelerating factor, CD59/homologous restriction factor 20 and membrane cofactor protein in human colorectal adenoma and cancer. Acta Med. Okayama 48: 271-277.
25. Brasoveanu, L. I., M. Altomonte, E. Fonsalti, F. Colizzi, S. Carol, M. R. Nicorta, I. Cattarossi, A. Cattelan, P. G. Natali, and M. Maio. 1996. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab. Invest. 74: 33-42.
26. Sakuma, T., K. Kodama, T. Hara, Y. Eshita, N. Shibata, M. Matsumoto, and T. Seya. 1993. Levels of complement regulatory molecules in lung cancer: disappearance of the D17 epitope of CD55 in small-cell carcinoma. Jpn. J. Cancer Res. 84: 753-759.
27. Niehans, G. A., D. L. Cherwitz, N. A. Staley, D. J. Knapp, and A. P. Dalmasso. 1996. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol. 149: 129-142.
28. Cheung, N. K., E. I. Walter, W. H. Smith-Mensah, W. D. Ratnoff, M. L. Tykocinski, and M. E. Medof. 1988. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J. Clin. Invest. 81: 1122-1128.
29. Finberg, R. W., W. White, and A. Nicholson-Weller. 1992. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J. Immunol. 149: 2055-2060.
30. fyn1. J. Immunol. 149: 3535-3541.